{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:23Z","timestamp":1794047423752,"version":"4.8.0"},"reference-count":42,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory checkpoint receptor that negatively regulates Tcell responses. CD226 competes with TIGIT for binding to the CD155 ligand, delivering a positive signal to the T cell. Here we studied the expression of TIGIT and CD226 in a cohort of 115 patients with chronic lymphocytic leukemia (CLL) and report expression of TIGIT and CD226 by leukemic cells. By devising a TIGIT\/CD226 ratio, we showed that CLL cells favoring TIGIT over CD226 are typical of a more indolent disease, while those favoring CD226 are characterized by a shorter time to first treatment and shorter progression-free survival after first treatment. TIGIT expression was inversely correlated to the B-cell receptor (BCR) signaling capacity, as determined by studying BTK phosphorylation, cell proliferation and interleukin- 10 production. In CLL cells treated with ibrutinib, in which surface IgM and BCR signaling capacity are temporarily increased, TIGIT expression was downmodulated, in line with data indicating transient recovery from anergy. Lastly, cells from patients with Richter syndrome were characterized by high levels of CD226, with low to undetectable TIGIT, in keeping with their high proliferative drive. Together, these data suggest that TIGIT contributes to CLL anergy by downregulating BCR signaling, identifying novel and actionable molecular circuits regulating anergy and modulating CLL cell functions.<\/jats:p>","DOI":"10.3324\/haematol.2022.282177","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T03:23:52Z","timestamp":1674098632000},"page":"2101-2115","source":"Crossref","is-referenced-by-count":14,"title":["The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy"],"prefix":"10.3324","volume":"108","author":[{"given":"Francesca","family":"Arruga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despoina","family":"Papazoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Iannello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Ioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Moia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Gaidano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Coscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Laurenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"D\u2019Arena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N.","family":"Allan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Furman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Vaisitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan G.","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Deaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"50399","doi-asserted-by":"crossref","unstructured":"Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005; 352(8):804-815.","DOI":"10.1056\/NEJMra041720"},{"key":"50400","doi-asserted-by":"crossref","unstructured":"Puente XS, Jares P, Campo E. Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. Blood. 2018; 131(21):2283-2296.","DOI":"10.1182\/blood-2017-10-764373"},{"key":"50401","doi-asserted-by":"crossref","unstructured":"Herishanu Y, Perez-Galan P, Liu D. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011; 117(2):563-574.","DOI":"10.1182\/blood-2010-05-284984"},{"key":"50402","doi-asserted-by":"crossref","unstructured":"Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011; 118(16):4313-4320.","DOI":"10.1182\/blood-2011-06-338855"},{"key":"50403","doi-asserted-by":"crossref","unstructured":"Packham G, Krysov S, Allen A. The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy. Haematologica. 2014; 99(7):1138-1148.","DOI":"10.3324\/haematol.2013.098384"},{"key":"50404","doi-asserted-by":"crossref","unstructured":"Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015; 126(5):573-581.","DOI":"10.1182\/blood-2015-03-567388"},{"key":"50405","doi-asserted-by":"crossref","unstructured":"Peters FS, Strefford JC, Eldering E, Kater AP. T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective. Haematologica. 2021; 106(5):1234-1243.","DOI":"10.3324\/haematol.2020.267914"},{"key":"50406","doi-asserted-by":"crossref","unstructured":"Vlachonikola E, Stamatopoulos K, Chatzidimitriou A. T cells in chronic lymphocytic leukemia: a two-edged sword. Front Immunol. 2020; 11:612244.","DOI":"10.3389\/fimmu.2020.612244"},{"key":"50407","doi-asserted-by":"crossref","unstructured":"Fiorcari S, Maffei R, Atene CG, Potenza L, Luppi M, Marasca R. Nurse-like cells and chronic lymphocytic leukemia B cells: a mutualistic crosstalk inside tissue microenvironments. Cells. 2021; 10(2):217.","DOI":"10.3390\/cells10020217"},{"key":"50408","doi-asserted-by":"crossref","unstructured":"Griggio V, Perutelli F, Salvetti C. Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia. Front Immunol. 2020; 11:594556.","DOI":"10.3389\/fimmu.2020.594556"},{"key":"50409","doi-asserted-by":"crossref","unstructured":"Arruga F, Gyau BB, Iannello A, Vitale N, Vaisitti T, Deaglio S. Immune response dysfunction in chronic lymphocytic leukemia: dissecting molecular mechanisms and microenvironmental conditions. Int J Mol Sci. 2020; 21(5):1825.","DOI":"10.3390\/ijms21051825"},{"key":"50410","doi-asserted-by":"crossref","unstructured":"DiLillo DJ, Weinberg JB, Yoshizaki A. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia. 2013; 27(1):170-182.","DOI":"10.1038\/leu.2012.165"},{"key":"50411","doi-asserted-by":"crossref","unstructured":"Drennan S, D'Avola A, Gao Y. IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus. Leukemia. 2017; 31(8):1686-1694.","DOI":"10.1038\/leu.2016.356"},{"key":"50412","doi-asserted-by":"crossref","unstructured":"Yu X, Harden K, Gonzalez LC. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009; 10(1):48-57.","DOI":"10.1038\/ni.1674"},{"key":"50413","doi-asserted-by":"crossref","unstructured":"Liu S, Zhang H, Li M. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ. 2013; 20(3):456-464.","DOI":"10.1038\/cdd.2012.141"},{"key":"50414","doi-asserted-by":"crossref","unstructured":"Le Mercier I, Lines JL, Noelle RJ. Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators. Front Immunol. 2015; 6:418.","DOI":"10.3389\/fimmu.2015.00418"},{"key":"50415","doi-asserted-by":"crossref","unstructured":"Chan CJ, Andrews DM, McLaughlin NM. DNAM-1\/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J Immunol. 2010; 184(2):902-911.","DOI":"10.4049\/jimmunol.0903225"},{"key":"50416","doi-asserted-by":"crossref","unstructured":"Johnston RJ, Comps-Agrar L, Hackney J. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014; 26(6):923-937.","DOI":"10.1016\/j.ccell.2014.10.018"},{"key":"50417","doi-asserted-by":"crossref","unstructured":"Deng C, Li W, Fei Y. Imbalance of the CD226\/TIGIT immune checkpoint is involved in the pathogenesis of primary biliary cholangitis. Front Immunol. 2020; 11:1619.","DOI":"10.3389\/fimmu.2020.01619"},{"key":"50418","doi-asserted-by":"crossref","unstructured":"Hasan MM, Nair SS, O'Leary JG. Implication of TIGIT(+) human memory B cells in immune regulation. Nat Commun. 2021; 12(1):1534.","DOI":"10.1038\/s41467-021-21413-y"},{"key":"50419","doi-asserted-by":"crossref","unstructured":"Catakovic K, Gassner FJ, Ratswohl C. TIGIT expressing CD4+ T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia. Oncoimmunology. 2017; 7(1):e1371399.","DOI":"10.1080\/2162402X.2017.1371399"},{"key":"50420","doi-asserted-by":"crossref","unstructured":"Vaisitti T, Braggio E, Allan JN. Novel Richter syndrome xenograft models to study genetic architecture, biology, and therapy responses. Cancer Res. 2018; 78(13):3413-3420.","DOI":"10.1158\/0008-5472.CAN-17-4004"},{"key":"50421","doi-asserted-by":"crossref","unstructured":"Vaisitti T, Arruga F, Vitale N. ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models. Blood. 2021; 137(24):3365-3377.","DOI":"10.1182\/blood.2020008404"},{"key":"50422","doi-asserted-by":"crossref","unstructured":"Arruga F, Bracciama V, Vitale N. Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. Leukemia. 2020; 34(2):462-477.","DOI":"10.1038\/s41375-019-0571-0"},{"key":"50423","doi-asserted-by":"crossref","unstructured":"Drennan S, Chiodin G, D'Avola A. Ibrutinib therapy releases leukemic surface IgM from antigen drive in chronic lymphocytic leukemia patients. Clin Cancer Res. 2019; 25(8):2503-2512.","DOI":"10.1158\/1078-0432.CCR-18-1286"},{"key":"50424","doi-asserted-by":"crossref","unstructured":"Chiodin G, Drennan S, Martino EA. High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL. Blood Adv. 2022; 6(18):5494-5504.","DOI":"10.1182\/bloodadvances.2021006659"},{"key":"50425","doi-asserted-by":"crossref","unstructured":"Tadmor T, Levy I. Richter transformation in chronic lymphocytic leukemia: update in the era of novel agents. Cancers (Basel). 2021; 13(20):5141.","DOI":"10.3390\/cancers13205141"},{"key":"50426","doi-asserted-by":"crossref","unstructured":"Condoluci A, Rossi D. Richter syndrome. Curr Oncol Rep. 2021; 23(3):26.","DOI":"10.1007\/s11912-020-01001-x"},{"key":"50427","doi-asserted-by":"crossref","unstructured":"Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018; 131(25):2761-2772.","DOI":"10.1182\/blood-2018-01-791376"},{"key":"50428","doi-asserted-by":"crossref","unstructured":"Beekman R, Chapaprieta V, Russinol N. The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia. Nat Med. 2018; 24(6):868-880.","DOI":"10.1038\/s41591-018-0028-4"},{"key":"50429","doi-asserted-by":"crossref","unstructured":"Ferreira PG, Jares P, Rico D. Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Res. 2014; 24(2):212-226.","DOI":"10.1101\/gr.152132.112"},{"key":"50430","doi-asserted-by":"crossref","unstructured":"Iannello A, Vitale N, Coma S. Synergistic efficacy of the dual PI3K-delta\/gamma inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models. Blood. 2021; 137(24):3378-3389.","DOI":"10.1182\/blood.2020010187"},{"key":"50431","doi-asserted-by":"crossref","unstructured":"Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J. TIGIT, the next step towards successful combination immune checkpoint therapy in cancer. Front Immunol. 2021; 12:699895.","DOI":"10.3389\/fimmu.2021.699895"},{"key":"50432","doi-asserted-by":"crossref","unstructured":"Freed-Pastor WA, Lambert LJ, Ely ZA. The CD155\/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell. 2021; 39(10):1342-1360.e14.","DOI":"10.1016\/j.ccell.2021.07.007"},{"key":"50433","doi-asserted-by":"crossref","unstructured":"Chauvin JM, Pagliano O, Fourcade J. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Invest. 2015; 125(5):2046-2058.","DOI":"10.1172\/JCI80445"},{"key":"50434","doi-asserted-by":"crossref","unstructured":"Shao Q, Wang L, Yuan M, Jin X, Chen Z, Wu C. TIGIT induces (CD3+) T cell dysfunction in colorectal cancer by inhibiting glucose metabolism. Front Immunol. 2021; 12:688961.","DOI":"10.3389\/fimmu.2021.688961"},{"key":"50435","doi-asserted-by":"crossref","unstructured":"Wolf C, Garding A, Filarsky K. NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. Int J Cancer. 2018; 142(2):322-333.","DOI":"10.1002\/ijc.31057"},{"key":"50436","doi-asserted-by":"crossref","unstructured":"Cerna K, Oppelt J, Chochola V. MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells. Leukemia. 2019; 33(2):403-414.","DOI":"10.1038\/s41375-018-0230-x"},{"key":"50437","doi-asserted-by":"crossref","unstructured":"Rozovski U, Harris DM, Li P. Activation of the B-cell receptor successively activates NF-kappaB and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer. 2017; 141(10):2076-2081.","DOI":"10.1002\/ijc.30892"},{"key":"50438","doi-asserted-by":"crossref","unstructured":"Gearing LJ, Cumming HE, Chapman R. CiiiDER: a tool for predicting and analysing transcription factor binding sites. PLoS One. 2019; 14(9):e0215495.","DOI":"10.1371\/journal.pone.0215495"},{"key":"50439","doi-asserted-by":"crossref","unstructured":"Hanna BS, Llao-Cid L, Iskar M. Interleukin-10 receptor signaling promotes the maintenance of a PD-1(int) TCF-1(+) CD8(+) T cell population that sustains anti-tumor immunity. Immunity. 2021; 54(12):2825-2841.e10.","DOI":"10.1016\/j.immuni.2021.11.004"},{"key":"50440","doi-asserted-by":"crossref","unstructured":"Wierzbinska JA, Toth R, Ishaque N. Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL. Genome Med. 2020; 12(1):29.","DOI":"10.1186\/s13073-020-00724-7"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282177\/75212","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282177\/75878","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10940\/75212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:13Z","timestamp":1794045793000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.282177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.282177","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,19]]}}}